Belvedere Trading’s Harmony Biosciences HRMY Stock Holding History

Belvedere Trading’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,955	Closed	-$119K	–	783
2024 Q2	$119K	Buy	+3,955	New	+$119K	﹤0.01%	418

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Belvedere Trading's HRMY Position: Q3 2024 in Review

Belvedere Trading sold out of Harmony Biosciences (HRMY) in Q3 2024, closing a stake of 3,955 shares — an estimated $119K sold.

Belvedere Trading first reported a position in HRMY in Q2 2024 and held it in 1 quarter. The position peaked at $119K in Q2 2024. 233 funds tracked by Wall St. Rank hold HRMY as of Q3 2024.

Belvedere Trading reported no remaining Harmony Biosciences position as of Q3 2024 after selling out during the quarter.
Belvedere Trading sold 3,955 Harmony Biosciences shares in Q3 2024, an estimated $119K.
Belvedere Trading first reported a position in Harmony Biosciences in Q2 2024 and held it in 1 quarter.
Belvedere Trading's Harmony Biosciences position peaked at $119K in Q2 2024.
233 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2024.

Based on Belvedere Trading's 13F filing for Q3 2024, filed 30 Oct 2024.